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INTERVIEW
Dr. Tian Xu
Thomas Ni and Rachel Rosenstein
Yale University School of Medicine
Tian Xu is professor and vice chairman of Genetics at Yale University and a Howard Hughes
Medical Institute investigator. His lab is working to understand the mechanisms of tumori-
genesis and metastasis using Drosophila and mouse models. Notably, Dr. Xu has developed
the powerful piggyBac transposon mutagenesis system, which has allowed investigators to
perform forward genetics in mammalian models. This approach should prove instrumental
in the identification of important genes involved in human diseases.
A lot of recent cancer research has
been focused on tumorigenesis and
the initial steps in tumor formation.
However, your lab also works on
metastasis, or the spread of cancer
to multiple organs. What has hin-
dered the study of metastasis and
why aren’t more labs working to un-
derstand the mechanism of cancer
spread?
What kills cancer patients is metastasis
of the cancer cells to other parts of the
body. If you look at how we’re doing in
terms of treating cancer patients, we’re
doing poorly. We’ve made significant ad-
vances in treating other diseases, but with
cancer treatment, the mortality rate is flat.
This is mostly because we don’t have an ef-
fective way to deal with metastasis.
Here is the problem: Cancer has the
second highest mortality rate in the past 25
years, and we haven’t made much progress,
even when we’ve made significant ad-
vances in other diseases like cardiovascular
diseases and even pneumonia or infection
in general. That is mostly because we still
don’t have an effective way of stopping
metastasis. In order to treat any disease,
you need to understand mechanism, and we
know very little about the mechanism of
metastasis because it is a very complicated
process. Most of the studies in the past have
focused on tumorigenesis, that is, how the
tumor starts. If you look at it, probably 99
percent of the cancer research labs are fo-
cused on tumorigenesis and not metastasis.
But metastasis is what kills cancer patients.
It’s very difficult to actually prevent tu-
morigenesis because we’re living longer
now and are able to accumulate more mu-
tations. Also, we pollute the environment,
which is getting worse and worse, and we
smoke and that induces lung cancer. I don’t
think you can prevent cancer, but once you
have it, most deaths are because cancer
cells spread. More labs don’t study metas-
tasis because it is very difficult to attack.
The most successful areas in cancer re-
search have been in tumorigenesis, because
human genetics has been very powerful in
identifying the genes that cause it. Human
geneticists can find families with a high in-
cidence of cancer and who have inherited
mutations that cause the tumor to occur.
Using genomic and other approaches, they
can identify tumor suppressor genes that
are mutated and cause these events to hap-
pen. It is very difficult to use a similar ap-proach to study metastasis. In order to have
metastasis, you need to have a tumor first.
In other words, if you want to identify a
family with inherited mutations that cause
or promote metastasis, you actually need to
have a family that also has inherited muta-
tions in tumor suppressors. The chance of
finding a family that has inherited mutations
in multiple genes that cause tumorigenesis
and promote metastasis is very small.
Besides the multiple mutations, the dif-
ficulty lies in several other areas of studying
metastasis. You could ask why can’t we
retroactively identify metastatic tumor cells
and then compare the mutations in the
metastatic cancer cells vs. the benign tumor
cells. If you do that, maybe you can provide
some clue. And the answer is yes, you can
do that, and indeed other groups are doing
that and looking at gene expression. How-
ever, researchers have been met with limited
success, because once the cancer cell be-
comes malignant, the genome destabilizes
so there are thousands of genes mutated. It’s
very difficult to look at a malignant cancer
cell and ask which mutations are actually
bystanders and which are causative.
The third level of difficulty comes from
the fact that the actual process of metastasis
itself is extremely complicated. Metastasis
involves the tumor cells growing in one
place, where they first need to degrade base-
ment membranes that engulf every organ
and then come out and have to travel — ei-
ther to the lymph nodes, blood vessels, or
other direct extensions into trouble. Once
the cells reach another target, they need to
degrade the basement membrane again to in-
vade. As you can see, this is a multi-organ,
multi-system problem in which the whole
organism is involved. You cannot simply
recreate metastasis in the Petri dish, because
multiple organs are involved.
The fourth reason that metastasis is dif-
ficult to study is that it takes a long time to
progress.You need accumulating mutations,
and the process involves the degradation of
basement membranes, cell migrations, and
invasion of other tissues for secondary
tumor formation. It’s a very elaborate
process, and in mammals it usually takes a
long time to occur. It’s very difficult to mon-
itor this process. Because of these four rea-
sons, it has been difficult to make progress.
A lot of cancer research has been
dedicated to establishing a mouse
model of tumorigenesis. Your lab has
successfully established a Drosophila
model for tumor progression and
metastasis. Can you explain the rea-
soning behind going away from the
mammalian system and to the fruit fly
in order to study cancer?
If you look at these four problems, you
realize that humans are difficult to work
with.Mostcancerresearchintissuecultureis
also not sufficient.The mouse is a much bet-
ter model for studying metastasis. However,
it is still very difficult to create models to
systematically look for genes that have mul-
tiple mutations. Right now, the metastasis
models in mice have mostly been mutating
tumor suppressors or oncogenes, then wait-
ingforspontaneousmutationsintheprimary
tumors driving them to progress. Also, as I
alreadymentioned,itisverydifficulttomon-
itor these processes because they take a long
time. For example, the basement membrane
is very difficult to monitor in the animal.
Thatiswhyweareactuallydevelopingmod-
els to study metastasis in the fruit fly. I want
to give credit to a very talented former stu-
dent, Ray Pagliarini.When he joined the lab,
we talked and I tried to sell him a project on
tumorigenesis,lookingatthe genesinvolved
in regulating organ size and organism size. I
was very excited, but after talking to him
multiple times he was not that excited. In a
desperate attempt to try to trick him, I said,
“Well … maybe we can work on crazy proj-
ects.” He said, “Yeah, crazy projects sound
great!”Onecrazyprojectwasmetastasis.He
actually spent more than two years using the
powerofDrosophilageneticstosetupasys-
tem that now allows us to systematically in-
terrogate the genome and look for mutations
that can promote metastasis.
Thisabilityhastakentwoyearstosetup
even in Drosophila, and it is impossible to
doinotherorganismsrightnow.Youcanfol-
low the tumor progression and actually see
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and things like that, and it’s just not possible
todothistypeofgeneticsinanyotherorgan-
ism. Right now, it’s very exciting because
these somatic cell tumors that develop in
flies basically exhibit all of the characteris-
ticsobservedinmalignanthumancancer:ag-
gressive proliferation/overgrowth, then
degradationofthebasementmembrane,then
migration and invasion, then secondary
tumor formation. We are very excited to un-
derstand the molecular and cellular mecha-
nisms underlying these invasive behaviors.
Flies are not going to be the same as hu-
mans;theywillbedifferent—evenmiceare
different from humans, we know that — but
I think they will help us understand some
basicfundamentalsaboutthemetastatic phe-
nomenon and help us develop potential ther-
apeutics. Actually, our past experience in
studying tumorigenesis and tumor suppres-
sor genes in flies has helped us a lot. We
identified somatic mutations that caused tu-
morsinflies,andbystudyingthis,oneofthe
things we have shown in the past several
yearsisthatthesearetuberoussclerosiscom-
plexes, two tumor suppressors identified in
humans by geneticists. However, people do
not know why mutations in these genes
cause tumors, and they don’t have effective
therapeutics to combat these mutations. We
have shown using fly genetics and biochem-
istry that these genes actually function in the
PI3K/Akt and S6K pathways. Not only that,
but if you block S6K activity, you can actu-
ally alleviate defects associated with tuber-
ous sclerosis.These results basically suggest
thatthesedownstreamcomponentsareeffec-
tive therapeutic targets for this disease and
other cancers. This is very exciting, because
we are the first ones to show this pathway
using Drosophila genetics and biochemistry,
but now the pathway has been shown to be
conserved in mice, rats, and human patients
as well. More than 50 percent of human can-
cers have mutations in this pathway; it’s a
major cancer pathway. Furthermore, the
FDA has approved a clinical trial for these
compounds originally used for immunosup-
pression because we have shown that target-
ing this pathway can alleviate tuberous
sclerosis-associated defects and the pathway
has been conserved in humans and mice.
You can see that fly studies can help de-
fine major cancer pathways and also lead to
clinical trials and therapy. We hope that an
understanding of the metastatic phenome-
non, which is a very difficult phenomenon
that needs the whole organism to study, can
be studied in the fruit fly to start to under-
stand the biology. Hopefully, some of the
pathways will be conserved from fly to
mouse to human, and this knowledge can be
translated to help develop effective therapies
against metastasis.
Do you envision that the genetic
techniques that make Drosophila an
advantageous model system to study
biology and diseases like cancer can
one day be made available in higher
organisms such as mice?
That’s exactly our dream!The answer is
definitely yes. Fruit flies are invertebrates,
and the only reason we use organisms like
fruitfliesandC.elegansisbecauseofthege-
netic power. We can do forward genetic
screens. We can do whole organism studies.
Imagine if we could do these things directly
inamammal.Thenwecouldlearnalotmore.
The problem is that in the past, we could not
dothat.Oneofthelimitationsisthatwecould
notdoforwardgeneticscreensinmammalian
systems. The mouse is a powerful genetic
model and a powerful disease model, but the
main approach has been reverse genetics.
That is, using homologous recombination to
knock out a gene in an embryonic stem cell
and injecting those cells into blastocysts,
transplanting chimera embryos into false
mothers by doing surgeries, and hoping they
willtransmit.Thatprocessisfantasticandhas
revolutionized mouse genetics and allowed
us to manipulate the mouse genome. How-
ever, it still has limitations, because it’s too
expensive, laborious, and technically chal-
lenging.Also, reverse genetics relies on a lot
of speculation, guessing which genes are im-
portant for this process and then knocking
them out and studying them. We think we’re
smart, but we’re not smart enough.When we
knock these genes out, past experience tells
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time and these genes do not exhibit the phe-
notypesweexpect.We’rejustnotassmartas
the organism.
If you look at the past several decades,
we have learned the most about modern bi-
ology from an approach called forward ge-
netics or forward genetic screens. That is,
not to be biased in thinking which gene is
important in a process, but rather to look for
organisms or human beings with a pheno-
type or a disease.After that, you can identify
which genes are causing the defect and
which are causing the disease. You can dis-
sect those genes and study molecular mech-
anisms. It is really painful to see that in
mammals such a screen is not possible. Al-
though people are conducting chemical mu-
tagenesis in mice, once you have the
mutation it is very difficult to map it and
know which genes cause it.We have wanted
to do this type of genetics in mammals for a
long time; we’ve tried for 10 years. In 1996,
when I applied for Investigatorship at the
Howard Hughes Medical Institute (HHMI),
I proposed that we wanted to improve the
mouse system so we could do the type of ge-
netics we were doing in fruit flies and in C.
elegans. The wonderful thing is I think I’m
extremely lucky that we have a collection of
very talented and brave young men and
women in the lab, and they continue to try
all kinds of different methods. Even with all
of the failures, they’re still willing to take
risks and try crazy projects.Ayear and a half
ago, that led us to a major breakthrough
when we discovered a modified transposon
that can effectively work in mammalian sys-
tems, in human cells, mouse cells, and the
mouse germline. Now for the first time, we
can systematically mutate genes and look for
a phenotype.
Transposon technology saw wide
use in Drosophila, and now you have
shown that piggyBac mobilizes in
mice. Could you talk about its poten-
tial influence on cancer research?
I think the technique will really offer
fantastic opportunities for many diseases,
not just cancer. This will be the first time in
mammals that we will be able to systemati-
cally, on a large scale, mutate genes and
know which genes are mutated and look for
a phenotype. That opens wonderful oppor-
tunities. Just imagine, all of the screens, all
of the discoveries you have never made —
now you can just compress. More than 6,000
human diseases are estimated to be caused
by a single gene mutation. We’ve identified
very few; I think the last number was 1,700
known gene mutations causing disease.You
mentioned cancer, which, of course, is a
major disease. Hypertension is another.
Alzheimer’s. These are the things on peo-
ple’s minds.What about other diseases? For
example, one third of the patients in our
Yale-New Haven Hospital neurosurgery
wards are actually hydrocephalus babies.
These are the babies that have swollen
brains. We do not know which gene alter-
ations actually cause this.We know there are
genetic factors, but we do not have the
names of the genes.Approximately 1 out of
every 5 women will develop polycystic fi-
broids and almost 10 percent of women have
endometriosis.The genetic determinants for
these conditions remain unknown.That’s in-
credible to me.The hope is that now you can
systematically mutate genes in a mammalian
system and identify the genetic basis for
many diseases, which is very exciting. Not
only that, but there are about 5,000 to 7,000
orphan diseases.These are diseases affecting
small percentages of the population. Al-
though it’s small, if you add the numbers up,
it’s a huge percentage of people affected.
Pharmaceutical companies are not interested
in developing therapies because there’s not
enough of a market. The National Institutes
of Health doesn’t have enough money.
What’s the solution? By systematically mu-
tating genes, we can identify the cause of
many of these orphan diseases. Our hope,
our dream, is that we will be supported, and
hundreds of young, talented men and
women with Ph.D. degrees and M.D. de-
grees will join us and use screens to focus
on a particular disease, identify the genetic
cause, and take this wisdom to study the
mechanism and develop therapeutics. That
really would be a dream come true.
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contribute to the study of diabetes, obesity,
cardiovascular disease, and tumor spread.
For example, we are interested in longevity,
in how long you can live. In C. elegans and
in flies, experiments tell us that a single gene
manipulation can increase longevity tremen-
dously. In C. elegans, a single gene alter-
ation can increase longevity by six times. If
we extrapolate that to humans, that means
600 years old. So the real questions are: Can
we identify these gene alterations in mam-
mals that can significantly prolong longevity
and how long can we really live? Can we
live 600 years?Avery exciting experiment.
Of course, if we can truly live 600 years,
other problems will occur, but the biology
will be very cool. Now it’s possible because
we can systematically mutate these genes.
All we need is a little bit of money to keep
all of the mice and all of the mutant mice liv-
ing, and we can look to see which ones dou-
ble, triple, or six times their longevity. How
much would it cost? Thirty million dollars.
Not much, if you think about the question.
We can do it. I think if many people knew
this, they would want to do it. The technol-
ogy is really here, and all we need are two
things: young, talented brave people that can
take a run and work on things they’re inter-
ested in, either disease or biology, and we
also need people who can financially help to
say here is a disease, or here is a biological
process that you should work on. That
would be very exciting.
What do you see as being the next
big breakthrough in cancer re-
search?
I do not know. If you look at the past
successful history, breakthroughs often
come through unexpected areas, and that’s
why we need to support basic research, even
for people who work with fruit flies. It’s
very difficult to predict where the break-
throughs will come from, but I think thera-
peutic breakthroughs will come from
conquering metastasis. I think that’s the ul-
timate goal. If we can manage or control
metastasis — not even completely stop it but
just manage the situation — I think we will
turn cancer into a chronic disease, and that’s
a success. In my mind, I don’t think we can
cure cancer. I think most likely we’ll make
cancer a chronic, controlled disease. Plus, I
think more and more people are conscious
about the environment, and hopefully we’ll
do less harm to ourselves in the future. I’ve
already seen that the number of smokers has
dramatically dropped in the United States,
and that’s a big help. Hopefully, the rest of
the world will do the same.
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